MedTrace Logo

Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia

NCT07517744 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-04-08

No results posted yet for this study

Summary

Anemia is a common and debilitating complication of end-stage kidney disease (ESKD) that is associated with reduced quality of life and high morbidity and mortality. ESKD-related anemia is associated with many adverse comorbidities and outcomes; however, normalizing the levels of hemoglobin proved to be insignificant in improving most adverse outcomes. This study aims to evaluate the real-world effectiveness and safety of an ESA and a HIF-PHI in patients with CKD-related anemia.

Conditions

  • CKD Anemia
  • CKD Anemia in Stable Dialysis Patients

Sponsors & Collaborators

  • Misr International University

    collaborator OTHER

  • October 6 University

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-06-12
Completion
2025-06-12

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07517744 on ClinicalTrials.gov